Health Catalyst Capital Management
Investments
28Portfolio Exits
4Funds
2About Health Catalyst Capital Management
Health Catalyst Capital Management is an independent private equity fund investing in growth-stage healthcare technology and technology-enabled services businesses that seek to improve the human condition and promote value-based care. Current and former investments include Cardiogram, PierianDx, Medal, Risalto, HealthMine, ReferWell, InsightIn, Artimis, 1DocWay, Board Vitals, Clareto and others.
Latest Health Catalyst Capital Management News
Nov 14, 2019
After fueling its seed round last year, Health Catalyst Capital Management again lead the startup's funding. Share Musculoskeletal digital health platform Risalto Health bagged $7 million in new funding from Health Catalyst Capital Management, the startup announced yesterday. WHAT THEY DO The New York-based company use artificial intelligence to find muscular and skeletal health providers in the user’s area. Patients navigate these selections through the company’s app, which acts as a digital concierge that helps select prompt, appropriate care for their condition. Risalto aims to partner with payers and providers alike to streamline patients’ access to care. According to the company, the platform has been shown to reduce patients’ pain scores by as much as 50%, and influences members’ care choices at a 95% success rate. Alongside Health Catalyst Capital Management, the company boasts Oxeon Venture Studio as an institutional investor. WHAT IT’S FOR In addition to funding improvements to the platform itself, Risalto said that these new dollars will help scale the digital musculoskeletal program across the nation. "Each day we spend working with patients it becomes more apparent that there is a lack of coordination and vital resources for those with MSK issues," Dr. Daniel Pizzarello, founder and CEO of Risalto, said in a statement. "We're excited to continue our partnership with HCCM to scale nationwide and help ensure that every patient gets the care that they deserve so that they can avoid dangerous drugs and unnecessary surgeries.” MARKET SNAPSHOT Yesterday’s announcement comes nearly a year and a half after Risalto’s $1.5 million seed round , which was also headed by Health Catalyst Capital Management. That same year saw fundings for similar concierge services addressing different areas of care, such as SteadyMD ( $2.5 million in March 2018 ) and Accolade ( $50 million in April 2018 ). Further, it was only two months ago that Firefly announced its $10.2 million Series A round , and the appointment of athenahealth’s former firebrand Jonathan Bush as its executive chairman. ON THE RECORD "Health Catalyst Capital has focused on MSK as a major pain point in the healthcare system. By investing a second time in Risalto Health as it transforms MSK care, Health Catalyst Capital is furthering its mission of improving healthcare system access and quality while lowering costs," Charles Boorady, founding managing director at Health Catalyst Capital Management, said in a statement. “We have been very impressed by the progress made by Dan and the team at Risalto since our last investment. We are excited now to support their scale-up and roll-out to employers and health plans nationally. " Tags:
Health Catalyst Capital Management Investments
28 Investments
Health Catalyst Capital Management has made 28 investments. Their latest investment was in Vivante Health as part of their Series B on September 9, 2023.

Health Catalyst Capital Management Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
9/20/2023 | Series B | Vivante Health | $31M | Yes | 2 | |
1/31/2023 | Series D | Clearsense | $50M | No | 3 | |
1/9/2023 | Series B | Holmusk | $45M | No | dRx Capital, Heritas Capital, Northwell Holdings & Ventures, and Undisclosed Investors | 11 |
6/23/2022 | Series B | |||||
12/6/2021 | Series A - II |
Date | 9/20/2023 | 1/31/2023 | 1/9/2023 | 6/23/2022 | 12/6/2021 |
---|---|---|---|---|---|
Round | Series B | Series D | Series B | Series B | Series A - II |
Company | Vivante Health | Clearsense | Holmusk | ||
Amount | $31M | $50M | $45M | ||
New? | Yes | No | No | ||
Co-Investors | dRx Capital, Heritas Capital, Northwell Holdings & Ventures, and Undisclosed Investors | ||||
Sources | 2 | 3 | 11 |
Health Catalyst Capital Management Portfolio Exits
4 Portfolio Exits
Health Catalyst Capital Management has 4 portfolio exits. Their latest portfolio exit was Simplifeye on April 18, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
4/18/2023 | Acquired | 2 | |||
Date | 4/18/2023 | |||
---|---|---|---|---|
Exit | Acquired | |||
Companies | ||||
Valuation | ||||
Acquirer | ||||
Sources | 2 |
Health Catalyst Capital Management Fund History
2 Fund Histories
Health Catalyst Capital Management has 2 funds, including Health Catalyst Capital II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
6/1/2020 | Health Catalyst Capital II | Multi-Stage Venture Capital | Open | $50.75M | 3 |
12/28/2016 | Health Catalyst Capital |
Closing Date | 6/1/2020 | 12/28/2016 |
---|---|---|
Fund | Health Catalyst Capital II | Health Catalyst Capital |
Fund Type | Multi-Stage Venture Capital | |
Status | Open | |
Amount | $50.75M | |
Sources | 3 |
Health Catalyst Capital Management Team
2 Team Members
Health Catalyst Capital Management has 2 team members, including current Managing Partner, Charles Boorady.
Name | Work History | Title | Status |
---|---|---|---|
Charles Boorady | Managing Partner | Current | |
Name | Charles Boorady | |
---|---|---|
Work History | ||
Title | Managing Partner | |
Status | Current |
Compare Health Catalyst Capital Management to Competitors
Laureate Pharma is a company focused on the healthcare and pharmaceutical industry. It provides a range of services including the synthesis of pharmaceutical substances, the creation of finished dosage forms, and the development and launch of pulmonary drugs. The company primarily sells to the healthcare sector, with a focus on pharmacies and other pharmaceutical companies. It is based in Princeton, New Jersey.

Blaze Systems is a provider of total LIMS software solutions for the laboratory marketplace.

MedeAnalytics focuses on healthcare data analytics. The company offers solutions to transform complex healthcare data into actionable insights, with a focus on improving value-based care, population health, financial metrics, and patient outcomes. Their main services include providing analytics for revenue cycle management, value-based care, provider network management, and comprehensive dashboards for government Medicare and Medicaid programs. It was founded in 1994 and is based in Richardson, Texas.
Kryosphere provides customized biorepository, logistical, and clinical sample management services to companies with a critical biospecimen component. Kryosphere delivers secure, scalable solutions to customers ranging from small, emerging entities to large corporations worldwide.

Innovaccer is a healthcare technology company developing a data activation platform for a patient-centered, connected care delivery continuum. It creates a unified patient record for the healthcare providers and payer-use to enable collaborative care delivery. The company was founded in 2013 and is based in San Francisco, California.

Cedar Gate Technologies is a company that focuses on healthcare technology. The company offers a unified technology and services platform that provides analytics, business intelligence insights, and administrative solutions to improve care delivery. Its primary customers are payers, providers, employers, and administrative services organizations in the healthcare industry. It was founded in 2014 and is based in Greenwich, Connecticut.
Loading...